Bomchil advises Fundación Huésped in their contracting with CanSino Biologics Inc.

New BACK

Bomchil advises Fundación Huésped in their contracting with CanSino Biologics Inc.

Rafael M. Manóvil and Adrián Furman from Bomchil have advised Fundación Huésped in their contracting with CanSino Biologics Inc. and the pertinent participating health centers in Argentina, for the development of a new study phase III of a vaccine against SARS-CoV-2, which will be conducted  in health centers in the Buenos Aires Metropolitan Area (AMBA, in its Spanish acronym) and Mar del Plata.

The vaccine uses a viral vector approach,  it uses an ordinary cold virus (adenovirus) to which a COVID-19 specific protein is genetically added so as to be recognized by the immune system and, thus, generate immunity.

The development of CanSino Biologics aims for a single-dose vaccine with storage between 2 and 8 degrees, which facilitates the logistics in positive results are shown in the Phase III study. The study is randomized (receiving the vaccine or the placebo will depend on chance), double-blind (neither the volunteers nor the research team know if they received the vaccine or the placebo), controlled with placebo (an inert substance) and performed in parallel groups to assess immunogenicity (the ability to activate the immune system), and  the safety of a viral vector vaccine.

The study will last one year and will include 40,000 volunteers around the world.

Together with the study coordinated in Argentina by Fundación Huésped, the international multicenter study is being carried out in Chile, Mexico, Russia and Saudi Arabia.